In particular, VSL#3 has been shown to improve intestinal barrier function in DSS-induced colitis by preventing the reduction and redistribution of TJ proteins, specifically augmenting the expression of ZO-1, and by inhibiting increases in the apoptotic ratio [45]. The gene discussed is TJP1; the disease is colitis.